Loading stock data…
$10.85
Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition Corp. in the Financial Services sector is trading at $10.85 with a market capitalization of $263M. The stock is currently near its 52-week high of $10.89, remaining 2.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$136,934↑ | -$143,301↑ | -$2.09M↓ | -$263,703↓ | -$131,919 |
| Net Income | $1.73M↓ | $1.97M↑ | $212,958↓ | $2.18M↓ | $2.29M |
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more ...